Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
SDC1
REST API REST API
Homo sapiens
SDC1 is differentially expressed in 304 experiments: 166 organism parts: liver, lung, ... (164 more);, 264 disease states: normal, glioblastoma, ... (262 more);, 94 cell types 524 cell lines 34 compound treatments and 73 other conditions.
Synonyms syndecan, CD138, SYND1, SDC
Orthologs SDC1_BOVIN (Bos taurus)   Sdc1 (Rattus norvegicus)   Sdc (Drosophila melanogaster)   F1NV24_CHICK (Gallus gallus)   Sdc1 (Mus musculus)   sdc1 (Xenopus laevis)   SDC1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term focal adhesion, response to hydrogen peroxide, plasma membrane, protein binding, cytoplasm, response to toxin, protein complex, wound healing, membrane, extracellular region, response to cAMP, lipid metabolic process, integral to plasma membrane, canonical Wnt receptor signaling pathway, lipoprotein lipase activity, cytoskeletal protein binding, protein C-terminus binding, cell surface, myoblast development, response to calcium ion, striated muscle cell development, uropod, odontogenesis, glycoprotein binding, response to organic substance, lipoprotein metabolic process, ureteric bud development, response to glucocorticoid stimulus, Sertoli cell development
InterPro Term Syndecan, Neurexin-like
UniProt Accession P18827, E9PHH3, F8WCX9
Search EB-eye ENSG00000115884
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-17189, E-GEOD-15765, E-GEOD-803, E-GEOD-6573, E-GEOD-3526, ... (27 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-17482, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, ... (43 experiments)

Factor Value U/D Experiments
A549
2
E-GEOD-3202, E-GEOD-6013
AGS
2
E-MTAB-37, E-GEOD-15460
BT20
2
E-MTAB-37, E-MTAB-62
DU145
2
E-GEOD-17482, E-GEOD-20089
HCC2157
2
E-MTAB-37, E-MTAB-62
LNCaP
2
E-GEOD-14990, E-GEOD-14464
518 more value(s).


Cell type

studied in E-TABM-40, E-GEOD-22373, E-GEOD-21668, E-GEOD-19397, E-GEOD-3920, ... (46 experiments)

Factor Value U/D Experiments
monocyte
3
E-GEOD-22373, E-MEXP-2019, E-GEOD-11755
human foreskin fibroblast
2
E-GEOD-18265, E-GEOD-18147
squamous cell
1
E-GEOD-19397
dendritic cell-derived osteoclast
1
E-MEXP-2019
BDCA4+ dentritic cells
1
1
E-AFMX-5
monolayer recovery
1
E-GEOD-4219
88 more value(s).


Disease state

studied in E-GEOD-1615, E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-16363, ... (67 experiments)

Factor Value U/D Experiments
lung adenocarcinoma
4
E-MTAB-37, E-MTAB-62, E-GEOD-2514, E-MEXP-231
prostate carcinoma
3
E-MEXP-1327, E-MTAB-37, E-TABM-26
cervical carcinoma
2
E-MTAB-37, E-MTAB-62
chronic lymphocytic leukemia
2
E-GEOD-2466, E-GEOD-6691
colon carcinoma
2
E-MTAB-37, E-MTAB-62
colorectal adenocarcinoma
2
E-AFMX-5, E-MTAB-62
258 more value(s).


Compound treatment

studied in E-GEOD-6907, E-GEOD-5741, E-GEOD-15205, E-GEOD-5824, E-TABM-868, ... (20 experiments)

Factor Value U/D Experiments
lipopolysaccharide
2
E-TABM-868, E-MEXP-1958
interleukin-4 (Homo sapiens) + anti-CD40
1
E-GEOD-7307
NaOH
1
E-MEXP-2590
ox-LDL
1
E-GEOD-5741
AMP
1
E-MEXP-2285
vanadium pentoxide
1
E-GEOD-5339
28 more value(s).


Age at onset

studied in E-GEOD-21521

Factor Value U/D Experiments
GTE6
1
1
E-GEOD-21521
LT6
1
E-GEOD-21521


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21589, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-MEXP-1251, E-GEOD-2191, E-GEOD-2034, ... (7 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-5999, E-GEOD-1614, E-GEOD-3140, E-MEXP-2359, E-GEOD-4667, ... (7 experiments)

Disease staging
studied in E-GEOD-89, E-GEOD-19743, E-GEOD-22544, E-GEOD-3325, E-TABM-147, ... (6 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-GEOD-7578, E-GEOD-17385, E-GEOD-20847, E-MTAB-108, ... (7 experiments)

Genotype
studied in E-MEXP-1996, E-GEOD-2466, E-GEOD-22593, E-TABM-868, E-GEOD-18005, ... (13 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-13073, E-GEOD-12773, E-GEOD-20540, E-GEOD-20504, ... (12 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Her2 status
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-302, E-TABM-276, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-2466, E-MEXP-2069, E-GEOD-1926, ... (34 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-MEXP-561 ... (5 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-958, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-GEOD-426

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-1309, E-GEOD-21750, E-GEOD-1657, E-GEOD-3407, E-GEOD-846, ... (7 experiments)

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-1880, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

Replicate
studied in E-GEOD-10797, E-GEOD-19330, E-GEOD-18791

RNAi
studied in E-MEXP-2115, E-MEXP-101, E-GEOD-3697, E-MEXP-1857, E-GEOD-3485, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-17400

Sex
studied in E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-11886, E-GEOD-11428

Strain or line
studied in E-MEXP-1996, E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-16837, E-GEOD-19246

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-TABM-43, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.441 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM